Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.

Kchour G, Rezaee R, Farid R, Ghantous A, Rafatpanah H, Tarhini M, Kooshyar MM, El Hajj H, Berry F, Mortada M, Nasser R, Shirdel A, Dassouki Z, Ezzedine M, Rahimi H, Ghavamzadeh A, de Thé H, Hermine O, Mahmoudi M, Bazarbachi A.

Retrovirology. 2013 Aug 20;10:91. doi: 10.1186/1742-4690-10-91.


Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).

Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H, Rezaee SA, Yazdi MT, Shirdel A, de Thé H, Hermine O, Farid R, Bazarbachi A.

Blood. 2009 Jun 25;113(26):6528-32. doi: 10.1182/blood-2009-03-211821. Epub 2009 May 1.


Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

Hermine O, Dombret H, Poupon J, Arnulf B, Lefrère F, Rousselot P, Damaj G, Delarue R, Fermand JP, Brouet JC, Degos L, Varet B, de Thé H, Bazarbachi A.

Hematol J. 2004;5(2):130-4.


A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma.

Hermine O, Allard I, Lévy V, Arnulf B, Gessain A, Bazarbachi A; French ATL therapy group.

Hematol J. 2002;3(6):276-82.


How I treat adult T-cell leukemia/lymphoma.

Bazarbachi A, Suarez F, Fields P, Hermine O.

Blood. 2011 Aug 18;118(7):1736-45. doi: 10.1182/blood-2011-03-345702. Epub 2011 Jun 14.


Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran.

Kchour G, Makhoul NJ, Mahmoudi M, Kooshyar MM, Shirdel A, Rastin M, Rafatpanah H, Tarhini M, Zalloua PA, Hermine O, Farid R, Bazarbachi A.

Leuk Lymphoma. 2007 Feb;48(2):330-6.


Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives.

Bazarbachi A, Hermine O.

Virus Res. 2001 Oct 30;78(1-2):79-92. Review.


Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.

Nasr R, Marçais A, Hermine O, Bazarbachi A.

Methods Mol Biol. 2017;1582:197-216. doi: 10.1007/978-1-4939-6872-5_15. Review.


Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma.

Bazarbachi A, Nasr R, El-Sabban ME, Mahé A, Mahieux R, Gessain A, Darwiche N, Dbaibo G, Kersual J, Zermati Y, Dianoux L, Chelbi-Alix MK, de Thé H, Hermine O.

Leukemia. 2000 Apr;14(4):716-21.


Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.

Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O.

J Clin Oncol. 2010 Sep 20;28(27):4177-83. doi: 10.1200/JCO.2010.28.0669. Epub 2010 Jun 28.


The efficacy of combined therapy of arsenic trioxide and alpha interferon in human T-cell leukemia virus type-1-infected squirrel monkeys (Saimiri sciureus).

Heraud JM, Mortreux F, Merien F, Contamin H, Mahieux R, Pouliquen JF, Wattel E, Gessain A, de Thé H, Bazarbachi A, Hermine O, Kazanji M.

Antiviral Res. 2006 Jul;70(3):132-9. Epub 2006 Feb 28.


Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells.

Kinpara S, Kijiyama M, Takamori A, Hasegawa A, Sasada A, Masuda T, Tanaka Y, Utsunomiya A, Kannagi M.

Retrovirology. 2013 May 20;10:52. doi: 10.1186/1742-4690-10-52.


The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma.

White JD, Wharfe G, Stewart DM, Maher VE, Eicher D, Herring B, Derby M, Jackson-Booth PG, Marshall M, Lucy D, Jain A, Cranston B, Hanchard B, Lee CC, Top LE, Fleisher TA, Nelson DL, Waldmann TA.

Leuk Lymphoma. 2001 Jan;40(3-4):287-94.


Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.

Ishitsuka K, Suzumiya J, Aoki M, Ogata K, Hara S, Tamura K.

Haematologica. 2007 May;92(5):719-20.


Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.

Mone A, Puhalla S, Whitman S, Baiocchi RA, Cruz J, Vukosavljevic T, Banks A, Eisenbeis CF, Byrd JC, Caligiuri MA, Porcu P.

Blood. 2005 Nov 15;106(10):3380-2. Epub 2005 Aug 2.


Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells.

Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y, Bex F, Hermine O, Staudt L, de Thé H, Bazarbachi A.

Blood. 2003 Jun 1;101(11):4576-82. Epub 2003 Jan 30.


Recent advances in the treatment of adult T-cell leukemia-lymphomas.

Utsunomiya A, Choi I, Chihara D, Seto M.

Cancer Sci. 2015 Apr;106(4):344-51. doi: 10.1111/cas.12617. Epub 2015 Mar 6. Review.


Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?

Nasr R, El Hajj H, Kfoury Y, de Thé H, Hermine O, Bazarbachi A.

Viruses. 2011 Jun;3(6):750-69. doi: 10.3390/v3060750. Epub 2011 Jun 14. Review.

Supplemental Content

Support Center